Table 3.
The efficacy of crizotinib in Asian and non-Asian populations
| ID Numbers | Number of patients
|
ORR (%)
|
PFS (months)
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Overall | Asian (%) | Overall | Non-Asian | Asian | Chinese | Overall | Non-Asian | Asian | Chinese | |
| PROFILE 100132 | 149 | 41 (28) | 60.8 | 54.8 | 76.9 | – | 9.7 | – | – | – |
| PROFILE 10052 | 259 | 93 (36) | 59.8 | 54 | 70 | 73.9 | 8.1 | – | – | 7 |
| PROFILE 10073 | 347 | 157 (45) | 65 | – | 75 | – | 7.7 | 7.1 | 8.1 | – |
| PROFILE 10144 | 343 | 157 (46) | 74 | 72 | 70 | – | 10.9 | – | 13.6 | – |
Note: –, the data were not available.
Abbreviations: ORR, objective response rate; PFS, progression-free survival.